Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Accounts Payable

Accounts Payable at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$21.4M-212%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's accounts payable?
Acadia Pharmaceuticals (ACAD) reported accounts payable of $1.34M in Q1 2026.
How has Acadia Pharmaceuticals's accounts payable changed year-over-year?
Acadia Pharmaceuticals's accounts payable decreased by 29.4% year-over-year, from $1.9M to $1.34M.
What is the long-term trend for Acadia Pharmaceuticals's accounts payable?
Over 3 years (2021 to 2025), Acadia Pharmaceuticals's accounts payable has grown at a 48.4% compound annual growth rate (CAGR), from -$1.62M to -$5.29M.